In a recent paper in the Journal of Nuclear Medicine, Tagworks, in collaboration with Austrialian biotech company Avipep, describes an alternative radioimmunotherapy strategy based on separate administration of the tumor-homing agent and a fast clearing radioactive probe. This way, the unwanted high renal retention of low-molecular weight radiometal tumor-homing agents can …

Developing an antibody tag with improved pharmacokinetics and stability allowed Tagworks to achieve increased tumor uptake of a radiolabeled pretargeting probe. Even though this adapted tag exhibited a slight loss in reactivity, its use in a antibody (CC49-TCO) conjugate demonstrated a longer clearance half-life, improved tumor accumulation and increased in …

Approaches that use in vivo chemistry to enable non-invasive molecular imaging and therapy are much sought after. Taking the recent achievements in pretargeted radioimmuno-imaging and -therapy in mice as a starting point, the Tagworks team discuss how the application scope of this approach can eventually be extended towards humans. Read …

Tagworks' pretargeting technology can boost tumor/non-tumor ratios compared with conventional radioimmunoimaging and -therapy. Published in Journal Nuclear Medicine 2013, 54, 11, 1989-1995 doi:10.2967/jnumed.113.12.3745

Antibody tags with 10-fold increased reactivity and enhanced in vivo stability - Check the paper on 'Highly reactive trans-cyclooctene tags with improved stability for Diels-Alder chemistry in living systems' published in Bioconjugate Chemistry 2013, 24 ,7, 1210-1217 doi:10.1021/bc400153y